Amphastar Pharmaceuticals AMPH Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amphastar Pharmaceuticals's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amphastar Pharmaceuticals's total liabilities & equity?
- Amphastar Pharmaceuticals (AMPH) reported total liabilities & equity of $1.65B in Q1 2026.
- How has Amphastar Pharmaceuticals's total liabilities & equity changed year-over-year?
- Amphastar Pharmaceuticals's total liabilities & equity increased by 1.3% year-over-year, from $1.63B to $1.65B.
- What is the long-term trend for Amphastar Pharmaceuticals's total liabilities & equity?
- Over 5 years (2020 to 2025), Amphastar Pharmaceuticals's total liabilities & equity has grown at a 20.9% compound annual growth rate (CAGR), from $631.24M to $1.63B.
- What does total liabilities & equity mean?
- Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.